Teva Announces Appointment of New Global R&D and Chief Medical Officer
01 Juillet 2022 - 2:34PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today the appointment of Eric A. Hughes, MD, PhD as
Executive Vice President, Global R&D and Chief Medical Officer.
Dr. Hughes will begin his employment on August 1, 2022, and will be
based out of Teva's U.S. headquarters in Parsippany, NJ.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220701005225/en/
(Photo: Business Wire)
Dr. Hughes joins Teva with nearly 20 years of experience in all
phases of drug development in leading global pharmaceutical
companies, most recently as Senior Vice President of Clinical
Development and Translational Medicine at Vertex Pharmaceuticals,
and prior to that as Head of the Immunology, Hepatology &
Dermatology Global Development Unit at Novartis.
"Eric brings nearly 20 years of leadership roles with a proven
track record in a variety of R&D functions for global
pharmaceutical companies, and has a successful record of
accomplishment fostering productive collaborations with key opinion
leaders and patient advocacy groups,” said Kåre Schultz, Teva's
President and CEO. "As an accomplished scientist with specialty
training in infectious diseases and immunology, combined with his
track record of leading clinical development activities and talent
across multiple therapeutic areas around the globe, I believe Eric
has the experience and expertise to lead our Global R&D
function and execute on the company-wide vision for innovation and
growth going forward."
Dr. Hughes stated, "I am thrilled to join Teva's executive
management team and lead its unique, integrated Global R&D
organization. Building on Teva's strong heritage of value creation,
we have a tremendous opportunity to bring meaningful specialty,
biologics and generics medicines to patients worldwide."
Kåre Schultz, President and Chief Executive Officer, stated, "On
behalf of the Board of Directors and our leadership team, I would
also like to take this opportunity to thank Dr. Hafrun
Fridriksdottir for over 25 years of service to Teva and its legacy
companies. Hafrun has been an integral part of my Executive
Management team and I wish her good luck as she embarks on her next
adventure."
Eric A. Hughes bio
Dr. Hughes has held senior positions at Vertex Pharmaceuticals,
a U.S. based global biotechnology company and at Novartis. He
launched his career in the pharmaceutical industry in 2004, in
early clinical research at Bristol Myers-Squibb Company and then at
Schering-Plough Research Institute. He then had a one-year stint at
Merck Research Laboratories as Director of Clinical Research for
Clinical Hepatology before returning to Bristol Myers-Squibb in
2010.
Dr. Hughes was the Medical Lead in Global Clinical Research for
Virology at Bristol Myers-Squibb and his career there culminated as
Head of Virology, Fibrotic Diseases, Genetically Defined Diseases,
Autoimmunity, and Cardiology Exploratory Clinical &
Translational Research where he managed teams responsible for
discovery medicine and biomarkers, driving the development from
First-in-Human to Proof of Concept. He also led due diligence and
integration teams.
Dr. Hughes earned his MD and PhD at Yale School of Medicine. He
completed his medical residency with the Department of Internal
Medicine at Yale New Haven Hospital/Yale University School of
Medicine, and a Fellowship in Infectious Diseases at the Yale
University School of Medicine. He is a prolific and widely
published scientist, co-authoring more than 30 articles in
peer-reviewed scientific journals and a deep passion for helping
patients.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to our business and operations
in general, including our ability to attract, hire and retain
highly skilled key personnel, our ability to successfully compete
in the marketplace, including our ability to develop and
commercialize biopharmaceutical products, competition for our
specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our
ability to achieve expected results from investments in our product
pipeline, our ability to develop and commercialize additional
pharmaceutical products, and the effectiveness of our patents and
other measures to protect our intellectual property rights; our
substantial indebtedness; uncertainty regarding the COVID-19
pandemic and the governmental and societal responses thereto; our
ability to successfully execute and maintain the activities and
efforts related to the measures we have taken or may take in
response to the COVID-19 pandemic and associated costs therewith;
compliance, regulatory and litigation matters, including failure to
comply with complex legal and regulatory environments; other
financial and economic risks; and other factors discussed in our
Quarterly Report on Form 10-Q for the first quarter of 2022 and in
our Annual Report on Form 10-K for the year ended December 31,
2021, including in the section captioned “Risk Factors.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220701005225/en/
IR Contacts United States Ran Meir (267) 468-4475
Israel Yael Ashman 972 (3) 914-8262
PR Contacts United States Kelley Dougherty (973)
658-0237 Israel Eden Klein 972 (3) 906-2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024